GEN Exclusives

More »

GEN News Highlights

Back to Item »

Sucampo and Takeda Report Negative Results in One of Two Phase III Trials with Bowel Dysfunction Drug

Lubiprostone, which is already approved in related indications, did not meet its primary endpoint as a therapy for opioid-induced bowel dysfunction.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?